Fangsheng Green Chemical Pharmaceutical Co., Ltd. (referred to as "FSGC"), founded in September 2015, is a wholly-owned subsidiary of Hunan Fangsheng Pharmaceutical Co., Ltd. (referred to as "Fangsheng Pharmaceutical", stock code:603998) , which is a CDMO pharmaceutical company which combined with the R&D research, production and sales of Chemical API, Intermediates and Traditional Chinese medicine extracts.

Fangsheng Green Chemical Industrial Park covers a total area of 150 mu, with a planned investment of 1 billion yuan. FSGC has finished the construction of Chemical APIs Building, Traditional Chinese medicine extracts Building, Preparation products Building, comprehensive products Building and some other supporting utilities. Now, there are about 600m³ of chemical synthesis, with 1000 tons output of APIs and pharmaceutical intermediates. What’s more, there are areas of 13 thousands㎡ for traditional Chinese medicine extracts, which can process 5000 tons of traditional Chinese medicinal materials terminally. By 2025, Fangsheng Green Chemical Industrial Park will achieve an annual output value of 1 billion yuan after it is fully completed and put into operation.

As the wholly-owned subsidiary of Fangsheng Pharmaceutical, FSGC depends on the platform and scientific research advantages of Fangsheng Pharmaceutical (Fangsheng Pharmaceutical has the scientific research platforms such as the National Enterprise Technology Center, Hunan Provincial Enterprise Technology Center, Provincial Cardio Cerebral Vascular Engineering Research Center and National Postdoctoral Research Workstation. It has obtained 113 national drug approval numbers, 19 national new drug certificates, 30 domestic patents and 2 international patents), FSGC are trying to build a production platform with green chemical technologies such as microchannel continuous flow and enzyme catalytic reaction as the carrier, and become a integrator of proton pump inhibitor, cardiovascular system drugs, and endocrine system drugs.

FSGC will always keep market-oriented, talent-centered and innovation-driven to build core competitiveness and strive for the new breakthroughs in the company's development.